NextCure's NC410-pembrolizumab trial ends after Phase 1b; Part 2 never launched
NextCure terminated its Phase 1b/2 study of NC410 plus Merck's pembrolizumab in solid tumors, with results now posted after enrolling 97 participants.
This week's sole update covers NextCure's discontinued combination trial with Merck.
- NC410 plus pembrolizumab (Keytruda), Phase 1b/2, in advanced unresectable or metastatic solid tumors, was marked terminated. The sponsor said this was following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.1 The study had an actual enrollment of 97 participants1 and primary completion listed as April 30, 2025, with results first posted August 13, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.